U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235709) titled 'Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study' on Nov. 14.
Brief Summary: This is a prospective observational study. All patients will initiate and maintain treatment with agalsidase alfa during the study period. All patients will receive a full standard of care concomitant medication for the treatment of their cardiac condition. Twenty-five patients with genetically confirmed Anderson-Fabry disease will undergo PET-CMR at baseline and after 12 months of treatment with Agalsidase Alfa for follow-up.
Study Start Date: Nov., 2025
Study Type: OBSERVATIONAL
Condition:
Fab...